JP2013528599A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528599A5 JP2013528599A5 JP2013510350A JP2013510350A JP2013528599A5 JP 2013528599 A5 JP2013528599 A5 JP 2013528599A5 JP 2013510350 A JP2013510350 A JP 2013510350A JP 2013510350 A JP2013510350 A JP 2013510350A JP 2013528599 A5 JP2013528599 A5 JP 2013528599A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- pharmaceutical composition
- human
- cancer
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34500310P | 2010-05-14 | 2010-05-14 | |
| US61/345,003 | 2010-05-14 | ||
| PCT/US2011/036521 WO2011143614A1 (en) | 2010-05-14 | 2011-05-13 | Enhanced death receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013528599A JP2013528599A (ja) | 2013-07-11 |
| JP2013528599A5 true JP2013528599A5 (https=) | 2014-06-26 |
Family
ID=44121256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510350A Pending JP2013528599A (ja) | 2010-05-14 | 2011-05-13 | 増強デスレセプター・アゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130064838A1 (https=) |
| EP (1) | EP2569336A1 (https=) |
| JP (1) | JP2013528599A (https=) |
| AU (1) | AU2011252841B2 (https=) |
| CA (1) | CA2799177A1 (https=) |
| MX (1) | MX2012013144A (https=) |
| WO (1) | WO2011143614A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2831116A1 (en) * | 2012-03-28 | 2015-02-04 | Amgen Inc. | Dr5 receptor agonist combinations |
| ES2812208T3 (es) | 2013-03-14 | 2021-03-16 | Bristol Myers Squibb Co | Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| SG11201706024YA (en) | 2015-01-26 | 2017-08-30 | Macrogenics Inc | Multivalent molecules comprising dr5-binding domains |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| CA2118130A1 (en) | 1992-04-14 | 1993-10-28 | Jean M. J. Frechet | Dendritic based macromolecules and method of production |
| US6284236B1 (en) | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
| US6998116B1 (en) | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6342363B1 (en) | 1997-01-28 | 2002-01-29 | Human Genome Sciences, Inc. | Death domain containing receptor 4 nucleic acids and methods |
| US7528239B1 (en) | 1997-02-13 | 2009-05-05 | Immunex Corporation | Receptor that binds trail |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2005118854A1 (en) * | 2004-06-01 | 2005-12-15 | Centre Hospitalier Regional Et Universitaire De Tours | Fcgr3a gebotype and methods for evaluating treatment response to non-depleting antibodies |
| US8029783B2 (en) * | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| WO2006094269A2 (en) | 2005-03-03 | 2006-09-08 | Covx Technologies Ireland Limited | Anti-angiogenic compounds |
| WO2010138725A1 (en) * | 2009-05-28 | 2010-12-02 | Amgen Inc. | Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine |
-
2011
- 2011-05-13 AU AU2011252841A patent/AU2011252841B2/en active Active
- 2011-05-13 US US13/698,040 patent/US20130064838A1/en not_active Abandoned
- 2011-05-13 CA CA2799177A patent/CA2799177A1/en not_active Abandoned
- 2011-05-13 JP JP2013510350A patent/JP2013528599A/ja active Pending
- 2011-05-13 MX MX2012013144A patent/MX2012013144A/es not_active Application Discontinuation
- 2011-05-13 WO PCT/US2011/036521 patent/WO2011143614A1/en not_active Ceased
- 2011-05-13 EP EP11720711A patent/EP2569336A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ali et al. | Investigations into the role of ST2 in acute asthma in children | |
| Favero et al. | Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome | |
| Scotlandi et al. | Genomics and therapeutic vulnerabilities of primary bone tumors | |
| JP2013528599A5 (https=) | ||
| Qiu et al. | Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancer | |
| JP2014530819A5 (https=) | ||
| WO2012093262A3 (en) | Mutational analysis | |
| JP2016526016A5 (https=) | ||
| CA2972076A1 (en) | Combination of raf inhibitors and aurora kinase inhibitors | |
| Lee et al. | Polymorphism in the serotonin transporter protein gene in Maltese dogs with degenerative mitral valve disease | |
| Verim et al. | Association between laryngeal squamous cell carcinoma and polymorphisms in tumor necrosis factor related apoptosis induce ligand (TRAIL), TRAIL receptor and sTRAIL levels | |
| WO2005112544A3 (en) | Leptin promoter polymorphisms and uses thereof | |
| Zhou et al. | Single nucleotide polymorphisms in the promoter region of mir-133a-1 and in pre-mir-152 rs1707 may contribute to the risk of asthma in a Chinese Han population. | |
| KR20140096073A (ko) | 혈관신생 억제제에 대한 반응성 | |
| Machida et al. | Mutation analysis of the multidrug resistance protein 2 (MRP2) gene in a Japanese patient with Dubin–Johnson syndrome | |
| Kim et al. | DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population | |
| Ogawa et al. | Exploration of the genetic basis of GVHD by genetic association studies | |
| Ran et al. | Genetic studies of the protein kinase AKT1 in Parkinson's disease | |
| KR20140064923A (ko) | 혈관신생 억제제에 대한 반응성 | |
| Salem et al. | Genotype and allele frequencies of MDR-1 gene polymorphism in Jordanian and Sudanese populations | |
| WO2012038744A2 (en) | Detecting mutations | |
| Datkhile et al. | Association of genetic polymorphisms in XRCC4, XRCC5, XRCC6 and XRCC7 in cervical cancer susceptibility from rural population: a hospital based case-control study | |
| Murdock et al. | RHD deletion in a patient with chronic myeloid leukemia | |
| PATIL et al. | Association of p53 and p21 gene polymorphism and risk of gastrointestinal cancer in rural population of south western Maharashtra: A hospital based case-control study. | |
| WO2011068610A1 (en) | Methods for detecting risk of myelodysplastic syndrome by genotypic analysis |